Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)
Price and Volume
Detailed Quote| Volume | 1,845,287 |
| Open | 109.70 |
| Bid (Size) | 107.22 (100) |
| Ask (Size) | 111.49 (500) |
| Prev. Close | 109.84 |
| Today's Range | 109.70 - 112.65 |
| 52wk Range | 61.23 - 116.84 |
| Shares Outstanding | 142,334,900 |
| Dividend Yield | N/A |
Top News
More NewsPerformance
52-Week Range
5.5% below 52-week high
110.42
61.2352W Low
116.8452W High
1 Week
3.1% below 1-week high
106.651W Low
114.001W High
Halozyme Therapeutics, Inc. - Common Stock (HALO) traded between $61.23 and $116.84 over the past 52 weeks and last traded at $110.42, 5.5% below its 52-week high. Over the past week it ranged between $106.65 and $114.00.
Past 12 Months
1W
+$0.56
1M
+$2.11
3M
+$31.80
6M
+$43.34
YTD
+$40.11
1Y
+$45.22
HALO was +69.4% over the past year, +64.6% over six months, +57.0% year to date, +0.5% in the last week.
12 Months vs Market
HALO
+69.4%
DIA
+10.7%
SPY
+15.7%
QQQ
+22.9%
IWM
+13.1%
Over the past 12 months HALO returned +69.4% versus DIA (Dow) +10.7%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +22.9% and IWM (Russell 2000) +13.1%.
Volume & Liquidity
0.85× 3-mo avg
Today 1,845,287
3-mo avg 2.2M
1W
2.2M
1M
2.5M
3M
2.2M
6M
2.0M
YTD
1.9M
1Y
2.0M
HALO most recently traded 1,845,287 shares against a 3-month average daily volume of 2.2M.
More News
Read More
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
September 24, 2026
1 Cash-Producing Stock to Target This Week and 2 We Question
September 22, 2026
1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
August 31, 2026
3 Market-Beating Stocks for Long-Term Investors
August 28, 2026
1 Healthcare Stock with Exciting Potential and 2 We Avoid
August 27, 2026
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
August 24, 2026
Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
1 Profitable Stock to Research Further and 2 We Ignore
August 07, 2026
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
August 04, 2026
3 Growth Stocks Set to Flourish
August 03, 2026
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
July 24, 2026
1 Value Stock Worth Investigating and 2 Facing Headwinds
July 15, 2026
2 Reasons to Like HALO and 1 to Stay Skeptical
July 10, 2026
Frequently Asked Questions
Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 110.42
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 10/09/26 04:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 15.72B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 16B shares outstanding.